ライフサイエンスコーパス: anti-angiogenic

1 Sulf1 has been recently recognized to be anti-angiogenic.

2 (165) stimulates angiogenesis, VEGF(165)b is anti-angiogenic.

3 its immunomodulatory, anti-proliferative and anti-angiogenic actions, was effective in improving BCVA

4 e (AM) anti-inflammatory, anti-scarring, and anti-angiogenic actions.

5 erived factor, PEDF, which is known to exert anti-angiogenic actions.

6 that TIMP-2 possesses two distinct types of anti-angiogenic activities which can be uncoupled from e

7 helper T cell (TH1) immune stimulation, and anti-angiogenic activities.

8 assumed to be the receptor that mediates its anti-angiogenic activities.

9 chemokine (or platelet factor 4) with potent anti-angiogenic activity and differed only in three amin

10 Cleavage of CgA by thrombin abrogated its anti-angiogenic activity and generated fragments (lackin

11 bled into core/shell nanodrugs with combined anti-angiogenic activity and significantly reduced antic

12 AI-1, rPAI-1(23), that possesses significant anti-angiogenic activity and stimulates high levels of a

13 ProAgio also has anti-angiogenic activity and strongly inhibits growth of

14 Aspergillus fumigatus that is known for its anti-angiogenic activity by binding to human methionine

15 decreased angiogenesis, the mechanism of the anti-angiogenic activity has not been determined.

16 r receptor through which T2-TrpRS exerts its anti-angiogenic activity has not previously been identif

17 irectly involved in the microenvironment and anti-angiogenic activity in NPC development.

18 cells (designated EDM-TTF-1(+)) displayed an anti-angiogenic activity in the endothelial cell tube fo

19 amily members have been shown to have potent anti-angiogenic activity in vivo.

20 The rPAI-1(23) anti-angiogenic activity inhibits FGF2 pro-angiogenic fu

21 ctional in cell adhesion, and therefore, the anti-angiogenic activity is attributed exclusively to al

22 The anti-angiogenic activity of A-LHU was investigated both

23 alternative helix conformation enhances the anti-angiogenic activity of CXCL4L1 by reducing the glyc

24 We propose that ferritin blocks the anti-angiogenic activity of HKa by reducing binding of H

25 de a mechanistic basis for understanding the anti-angiogenic activity of semaphorin as well as the ph

26 ll adhesion in the human vasculature and the anti-angiogenic activity of the RGD-alpha3NC1 domain.

27 ished by the striking anti-proliferative and anti-angiogenic activity specific to mini TrpRS.

28 cently, we discovered that opticin possesses anti-angiogenic activity using a murine oxygen-induced r

29 Beside its anti-angiogenic activity, TSP2 also suppressed the produ

30 Ferritin binds to HKa and blocks its anti-angiogenic activity.

31 esting that anti-CLEC14A antibodies may have anti-angiogenic activity.

32 oma blood vessels, consistent with its known anti-angiogenic activity.

33 n 5 (D5) both have been shown to have potent anti-angiogenic activity.

34 angiogenesis assay, sorafenib showed potent anti-angiogenic activity.

35 ADAMTS-1 is also known to exhibit anti-angiogenic activity.

36 phanyl-tRNA synthetase (T2-TrpRS) has potent anti-angiogenic activity.

37 ective Stat3 inhibitor, on IFNalpha-mediated anti-angiogenic activity.

38 ons, agonism/antagonism of GPCR ligands, and anti-angiogenic activity.

39 iomolybdate (TM) is a potent anti-cancer and anti-angiogenic agent and has been investigated in a num

40 cated by the recent development of the novel anti-angiogenic agent bevacizumab (Avastin).

41 on is associated with a poor response to the anti-angiogenic agent bevacizumab in patients with color

42 ty acid (SCFA), acts classically as a potent anti-angiogenic agent in tumour angiogenesis models, som

43 However, the effectiveness of this anti-angiogenic agent is limited by the presence of inna

44 Importantly, treatment with the anti-angiogenic agent thalidomide or ATN-161 significant

45 se) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF recepto

46 ation, showed that sorafenib is an effective anti-angiogenic agent.

47 elial growth factor and acts primarily as an anti-angiogenic agent.

48 may attenuate untoward biological effects of anti-angiogenic agents and tumor hypoxia.

49 may attenuate untoward biological effects of anti-angiogenic agents and tumor hypoxia.Oncogene advanc

50 e development of novel, molecularly targeted anti-angiogenic agents for breast cancer therapies.

51 r the specificity exhibited by this class of anti-angiogenic agents for MetAP-2 over MetAP-1 and may

52 ors should be evaluated further as potential anti-angiogenic agents for treatment of CRC.

53 y is discussed, as are studies investigating anti-angiogenic agents for treatment.

54 in part explain the preferential effects of anti-angiogenic agents in older GBM and pave the way to

55 emonstrated the anti-tumor effects of varied anti-angiogenic agents in sarcoma cell lines and tumor m

56 The model also shows a response to anti-angiogenic agents similar to previously described i

57 We tested sunitinib and sorafenib, two oral anti-angiogenic agents that are effective in advanced re

58 We propose the use of anti-angiogenic agents, now being used in cancer regimen

59 o-angiogenic factors and inducing endogenous anti-angiogenic agents.

60 er, our data suggest that PCBs act as potent anti-angiogenic agents.

61 bition or fat-targeted knockdown of NPY2R is anti-angiogenic and anti-adipogenic, while reducing abdo

62 number of pharmacologic benefits, including anti-angiogenic and anti-inflammatory properties.

63 ginex is a synthetic beta-sheet peptide with anti-angiogenic and anti-tumor activity.

64 CXCL4L1 is a highly potent anti-angiogenic and anti-tumor chemokine, and its struct

65 ding properties and to an enhancement of its anti-angiogenic and anti-tumor effects.

66 be pivotal in the mechanism underpinning its anti-angiogenic and anti-tumorigenic activities.

67 ptor that has been studied primarily for its anti-angiogenic and anti-tumorigenic properties.

68 This is the first report that ADAMTS5 is an anti-angiogenic and anti-tumorigenic protein independent

69 These results identify important anti-angiogenic and anti-tumorigenic roles for PPARalpha

70 This anti-angiogenic and anti-tumour effect is more robust th

71 nucleus to the cytoplasm could be useful in anti-angiogenic and breast cancer therapies.

72 mpact of different scheduling strategies for anti-angiogenic and cytotoxic agents (either in monother

73 mer in the extracellular matrix; it has both anti-angiogenic and immunosuppressive properties.

74 etastatic miRNA network, identify ApoE as an anti-angiogenic and metastasis-suppressive factor, and u

75 pondin-1 (TSP-1)--known earlier for both its anti-angiogenic and proapoptotic actions.

76 Anti-angiogenic and vascular disrupting therapies rely o

77 ngiogenesis and represent a novel target for anti-angiogenic and vascular normalization therapies.

78 els of forms of full-length CgA and CgA1-76 (anti-angiogenic) and lower levels of fragments lacking t

79 EGF-GemC18-NPs were more anti-proliferative, anti-angiogenic, and pro-apoptotic.

80 uestion whether netrin-4 acts either pro- or anti-angiogenic, angiogenesis in the retina was assessed

81 unreported mechanism of action of TRC105, an anti-angiogenic anti-Endoglin antibody currently evaluat

82 The identification of anti-angiogenic/anti-tumorigenic properties of PPARalpha

83 l cancer has established the validity of the anti-angiogenic approach.

84 nesis stimulators to overcome the endogenous anti-angiogenic barrier.

85 al growth factor (VEGF), the main target for anti-angiogenic-based therapies, and interleukin-8 (IL-8

86 igh-VEGF tumors may be most likely to escape anti-angiogenics by upregulating VEGF, driving CSC self-

87 d agents are currently in clinical trials as anti-angiogenic cancer therapeutics.

88 s, identifying NG2 as a potential target for anti-angiogenic cancer therapy.

89 the NFkappaB pathway, in turn triggering an anti-angiogenic cascade, might inhibit tumorigenesis and

90 eutic substances, including neurotrophic and anti-angiogenic compounds or protein based biosimilars.

91 tion inhibitors, stem-cell targeted therapy, anti-angiogenic compounds, vaccines and immunomodulating

92 also be used to test the efficacy of pro-and anti-angiogenic compounds.

93 steal AML cells produce pro-inflammatory and anti-angiogenic cytokines and gradually degrade endostea

94 We have shown that the soluble anti-angiogenic domain of BAI1 (termed Vstat120) require

95 onducted to identify and to characterize the anti-angiogenic domains of TIMP-2, the endogenous MMP in

96 pected opportunity to repurpose axitinib, an anti-angiogenic drug approved for renal cancer, as an in

97 Here, the anti-angiogenic drug quininib was formulated into hyalur

98 ions posits new mechanisms for understanding anti-angiogenic drug resistance and presents an expanded

99 a-null tumors were sensitive to the targeted anti-angiogenic drug sunitinib but resistant to cytotoxi

100 While the anti-angiogenic drug thalidomide inhibits HIF-1-dependen

101 ring of tumor vascularity in response to the anti-angiogenic drug tivozanib.

102 Promising anti-angiogenic drugs are currently available; however,

103 A comparison of the clinical efficacy of anti-angiogenic drugs with their corresponding preclinic

104 f AMD can be treated to varying degrees with anti-angiogenic drugs, but geographic atrophy (GA) is an

105 to understanding angiogenesis and developing anti-angiogenic drugs, but most work only involves numer

106 Interestingly, anti-angiogenic drugs, such as bevacizumab, when used at

107 nsaturated fatty acids (PUFAs) have a highly anti-angiogenic effect in animal models.

108 d squamous NPC HK1 cells, but also showed an anti-angiogenic effect in the animal assay, revealing a

109 The anti-angiogenic effect of antagomir-132 was reflected by

110 This study is the first to demonstrate the anti-angiogenic effect of CLA in the brain, and suggests

111 reduction in blood vessel density due to the anti-angiogenic effect of dexamethasone.

112 The potent anti-angiogenic effect of miR-192 stems from its ability

113 been used to investigate the anti-tumor and anti-angiogenic effect of SFN.

114 The anti-angiogenic effect of thrombospondin-1 has been show

115 We show that hNSC-aaTSP-1 has anti-angiogenic effect on human brain and dermal microva

116 This anti-angiogenic effect was prevented by administration o

117 However, the mechanisms by which PCBs cause anti-angiogenic effects are unclear.

118 vating the Notch/Dll pathway and by inducing anti-angiogenic effects at the maternal-fetal interface.

119 Ets-1 not only rescued miR-199a-5p-dependent anti-angiogenic effects but also reversed miR-199a-5p-in

120 elated metalloprotease ADAMTS1, which exerts anti-angiogenic effects by cleavage of thrombospondins a

121 Here, we evaluated PCB-mediated anti-angiogenic effects by diverse but complementary app

122 omato fruit (TCMPs) have been shown to exert anti-angiogenic effects by inhibiting endothelial cell m

123 type 2 diabetes therapy, is associated with anti-angiogenic effects in conditions beyond diabetes.

124 alization in fibrosis might have detrimental anti-angiogenic effects leading to aggravated peritubula

125 We show that the anti-angiogenic effects of endorepellin cannot occur in

126 udy was to evaluate the in vitro and in vivo anti-angiogenic effects of ERbeta selective agonist, bet

127 8 MAPK as blocking its activity restored the anti-angiogenic effects of IGFBP-4 on VEGF-induced blood

128 Therefore, we investigated the anti-angiogenic effects of mTOR inhibitors.

129 ying mechanism for the anti-inflammatory and anti-angiogenic effects of SERPINA3K.

130 in vitro studies have reported both pro- and anti-angiogenic effects of Slits.

131 artner for TM601 is also consistent with the anti-angiogenic effects of TM601.

132 hanism of miR-21 mediating metformin-induced anti-angiogenic effects, providing important implication

133 ctly targets FGF2 and VEGF to facilitate its anti-angiogenic effects.

134 velopment of this peptidomimetic and for its anti-angiogenic effects.

135 signaling in endothelial cells, with potent anti-angiogenic effects.

136 r, transforming growth factor-beta1, and the anti-angiogenic endostatin levels in either serum or car

137 This anti-angiogenic environment is accompanied by subclinica

138 cular endothelial growth factor, VEGF) or an anti-angiogenic factor (endostatin) related to the prese

139 Finally, murine endoglin ECD-Fc acted as an anti-angiogenic factor that decreased blood vessel sprou

140 stigated the effect of miR200-b, a potential anti-angiogenic factor, on VEGF receptor 2 (VEGFR-2) exp

141 or cells is the repression of a key secreted anti-angiogenic factor, thrombospondin-1 (Tsp-1).

142 s supporting Netrin-4 as either a pro- or an anti-angiogenic factor.

143 ane proteoglycan and in the liberation of an anti-angiogenic factor.

144 ic cytokine IL-8 and increased levels of the anti-angiogenic factors activin-A and pigment epithelium

145 ein expression of several pro-angiogenic and anti-angiogenic factors in response to (1) a single acut

146 kappa opioid receptor (KOR) agonists act as anti-angiogenic factors in tumors.

147 to release of proinflammatory cytokines and anti-angiogenic factors into the maternal circulation.

148 clampsia (PE) are primarily driven by excess anti-angiogenic factors originating from the placenta.

149 Thrombospondin-1 (TSP-1) is one of the anti-angiogenic factors whose synthesis is driven by hyp

150 is, including a reset profile of pro- versus anti-angiogenic factors, apparently distinct for physiol

151 ion while exhibiting increased expression of anti-angiogenic factors, such as endostatin, and decreas

152 glomerular endotheliosis, and production of anti-angiogenic factors.

153 ombospondin-1 (TSP-1) and its receptor CD36, anti-angiogenic factors.

154 ving as chaperones, hormone transporters, or anti-angiogenic factors.

155 e known to stimulate the expression of other anti-angiogenic factors.

156 be regulated by the balance between pro- and anti-angiogenic factors.

157 l-2 expression is regulated by both pro- and anti-angiogenic factors; thus, it may play a central rol

158 sted an essential role for PML in IFNalpha's anti-angiogenic function.

159 We have identified anti-angiogenic functions for synthetic double stranded

160 d function of various proteins with pro- and anti-angiogenic functions.

161 ent of Hsa21 in Tc1 mice identified putative anti-angiogenic genes (ADAMTS1and ERG) and novel endothe

162 proliferation through the downregulation of anti-angiogenic genes such as Col4a2, Spry1 and Timp3, w

163 essed genes, non-genomic sequences, pro- and anti-angiogenic genes, and RNAi-incompetent siRNAs all s

164 s driven by changes in expression of several anti-angiogenic genes.

165 ese results show that although VEGF(165)b is anti-angiogenic in the mesentery, it does signal in endo

166 This MMRN2 peptide is anti-angiogenic in vitro and reduces tumour growth in mo

167 not TSR2 (the C-terminal TSR) of ADAMTS5 is anti-angiogenic in vitro.

168 GF exerted a protective effect against these anti-angiogenics in a matrigel matrix.

169 sels is not because the Ihh(-/-) skeleton is anti-angiogenic; in fact, in an ex vivo environment, bot

170 endothelial growth factor signals, pro- and anti-angiogenic inflammatory chemokine signals, and the

171 The existence of anti-angiogenic isoform (VEGF165b) in PAD muscle tissues

172 itors of SRPK1 switched splicing towards the anti-angiogenic isoform VEGF165b in PC-3 cells and decre

173 using current methods, and demonstrate that anti-angiogenic isoforms are not commonly expressed in m

174 A second set of anti-angiogenic isoforms termed VEGFAxxxb that utilise a

175 iogenic isoforms typified by VEGF-A165a, and anti-angiogenic isoforms typified by VEGF-A165b.

176 network perturbation by three multi-targeted anti-angiogenic kinase inhibitors.

177 lthough, a vast number of pro-angiogenic and anti-angiogenic mediators have been identified, one of t

178 Here, we examined how anti-angiogenic miR-221 and pro-angiogenic miR-130a affe

179 down-regulation of CD36, a receptor for the anti-angiogenic molecule thrombospondin-1 (TSP-1).

180 1 (sVEGFR-1, also known as sFlt-1; a potent anti-angiogenic molecule), and defective placental devel

181 ial to regulate the balance between pro- and anti-angiogenic molecules that influence the angiogenic

182 bioactive molecules, both growth factors and anti-angiogenic molecules.

183 o produce two families of isoforms, pro- and anti-angiogenic, only the former of which is upregulated

184 rowth factors and molecules with established anti-angiogenic or anticancer activities.

185 ibition of ATP synthesis is necessary for an anti-angiogenic outcome in cell-based assays.

186 MAD1/5/8 signalling results in both pro- and anti-angiogenic outputs, highlighting a poor understandi

187 ype 1 repeats were weakly inhibitory, but an anti-angiogenic peptide derived from this domain potentl

188 We report the protein expression of anti-angiogenic peptides (thrombospondin-1, TSP-1; and e

189 d the production of type IV collagen-derived anti-angiogenic peptides and the generation of bioactive

190 CD36-binding domain of thrombospondin-1 and anti-angiogenic peptides derived from this domain failed

191 prolonged activation of p38 may result in an anti-angiogenic phenotype that contributes to endothelia

192 ascular endothelial growth factor (VEGF) and anti-angiogenic pigment epithelium derived factor (PEDF)

193 peutic agents have been developed which have anti-angiogenic potential.

194 y actions and prohomeostatic bioactivity, is anti-angiogenic, promotes corneal nerve regeneration, an

195 The data suggest that SsnB may exert its anti-angiogenic properties in part by downregulating CCN

196 The results also highlight the anti-angiogenic properties of thalidomide and CC-5013 an

197 lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docetaxe

198 rrelidin, a compound with anti-microbial and anti-angiogenic properties, is a known inhibitor of bact

199 nal fragment of collagen XVIII known for its anti-angiogenic properties, is associated with neurologi

200 in with well established neuroprotective and anti-angiogenic properties.

201 t in part underlie its immunosuppressive and anti-angiogenic properties.

202 several other mechanisms in addition to its anti-angiogenic properties.

203 that counteracts prior claims of endogenous anti-angiogenic properties.

204 the molecular mechanism responsible for its anti-angiogenic property is unclear.

205 Soluble endoglin is an anti-angiogenic protein that is released from the placen

206 and characterized multiple novel variants of anti-angiogenic protein thrombospondin (aaTSP-1) that co

207 in combination with a peptidomimetic of the anti-angiogenic protein thrombospondin-1 (TSP-1 PM).

208 s paper, we report that the expression of an anti-angiogenic protein, thrombospondin-1 (TSP-1) is dow

209 and on endothelial cell surfaces to HKa, an anti-angiogenic protein.

210 nt alpha2(IV)NC1 domain is not only a potent anti-angiogenic reagent, but it also directly impacts tu

211 and Met inhibitors including cabozantinib in anti-angiogenic resistant RCC.

212 Knocking down endogenous Ets-1 simulated an anti-angiogenic response of the miR-200b mimic-transfect

213 dothelial cells (MVECs), for it to elicit an anti-angiogenic response.

214 The observed antiproliferative and anti-angiogenic responses to CX-4945 in tumor cells and

215 There were also higher levels of anti-angiogenic sFlt expression in the muscle and plasma

216 inase MEK5 are the upstream mediators of the anti-angiogenic signal by the natural angiogenesis inhib

217 dulates the crucial balance between pro- and anti-angiogenic signaling by activin receptor-like kinas

218 These results reveal that anti-angiogenic signaling through CD47 is highly redunda

219 mainly a vascular disease, caused by excess anti-angiogenic signalling in the peripartum period.

220 d through complex crosstalk between pro- and anti-angiogenic signals.

221 ), hypoxia also stimulates the production of anti-angiogenic signals.

222 re-activity studies showed that a functional anti-angiogenic site is located in the C-terminal region

223 d in the C-terminal region, whereas a latent anti-angiogenic site, activated by cleavage of Q76-K77 b

224 TNP-470, the first anti-angiogenic small molecule to enter clinical trials,

225 In summary, quininib is a novel anti-angiogenic small-molecule CysLT receptor antagonist

226 to be a potent stimulator for switching the anti-angiogenic SMC phenotype to the pro-angiogenic phen

227 novel concept that synthetic SMC exhibits an anti-angiogenic SMC phenotype, whereas contractile SMC s

228 tch in the expression of VEGF165 towards the anti-angiogenic splice isoform, VEGF165b, was seen in PC

229 suggesting that patients might benefit from anti-angiogenic strategies in the adjuvant setting.

230 ic properties that influence the response to anti-angiogenic strategies.

231 Given its position as an anti-angiogenic target in the treatment of human disease

232 identification of other endothelium-specific anti-angiogenic targets relevant to a broad spectrum of

233 ent predicted adverse effects of a reference anti-angiogenic thalidomide analog, 5HPP-33, on in vitro

234 oparticle that can potentially be used as an anti-angiogenic therapeutic agent in ovarian cancer.

235 genesis as well as testing anti-invasive and anti-angiogenic therapeutic approaches.

236 The model is then utilized to simulate anti-angiogenic therapeutic interventions targeting VEGF

237 VEGF biologics that have been used in ocular anti-angiogenic therapeutic regimes.

238 ea being widely used for validating pro- and anti-angiogenic therapeutic strategies for many disorder

239 ey angiogenic cytokine and a major target in anti-angiogenic therapeutic strategies.

240 rstanding of the mechanisms of resistance to anti-angiogenic therapies and better selection of patien

241 s they are critical sites for drug delivery, anti-angiogenic therapies and immunotherapy.

242 WHERE NEXT?: Although anti-angiogenic therapies are promising, the duration of

243 ch likely contribute to this remodeling, but anti-angiogenic therapies do not improve AML patient out

244 Anti-angiogenic therapies for cancer such as VEGF neutra

245 tional models can be used to predict optimal anti-angiogenic therapies in combination with other ther

246 Combined neuroprotective and anti-angiogenic therapies may be required to treat Mulle

247 n angiogenesis is inhibited, suggesting that anti-angiogenic therapies may not be sufficient to elimi

248 Moreover, anti-angiogenic therapies synergize with the first-line

249 gs provide strong implications for designing anti-angiogenic therapies that may differentially target

250 Anti-angiogenic therapies that target VEGF and the VEGF

251 are no effective treatments for patients on anti-angiogenic therapies whose tumours progress.

252 macular surgery, photodynamic therapies, and anti-angiogenic therapies, as well as small pilot studie

253 Anti-angiogenic therapies--which 'normalize' the abnorma

254 (NPs) holds promise in molecular imaging and anti-angiogenic therapies.

255 naling that could serve as a basis for novel anti-angiogenic therapies.

256 rapeutic for use in combination with current anti-angiogenic therapies.

257 ibition and to suggest molecular targets for anti-angiogenic therapies.

258 anti-vascular endothelial growth factor and anti-angiogenic therapies.

259 ucial to the further development of pro- and anti-angiogenic therapies.

260 ould provide a novel approach for developing anti-angiogenic therapies.

261 may represent a new opportunity for pro- and anti-angiogenic therapies.

262 esis regulation is needed to improve current anti-angiogenic therapies.

263 e efficacy of new therapeutic strategies and anti-angiogenic therapies.

264 inically relevant mechanism of resistance to anti-angiogenic therapy and combined inhibition of angio

265 is and support the potential clinical use of anti-angiogenic therapy as a novel treatment modality fo

266 As an example, we demonstrate using VAI that anti-angiogenic therapy can improve microcirculation and

267 al of low molecular weight heparin (LMWH) in anti-angiogenic therapy has been tempered by poor in viv

268 metastases, a setting in which results with anti-angiogenic therapy have been disappointing.

269 nts lacking stromal Cav-1 might benefit from anti-angiogenic therapy in addition to standard regimens

270 hese results have important implications for anti-angiogenic therapy in breast cancer patients.

271 r the use of SRPK1 inhibition as a potential anti-angiogenic therapy in PCa.

272 Anti-angiogenic therapy might also lead to mobilisation

273 Resistance to anti-angiogenic therapy might implicate alternative pro-

274 A/FGF18 pathway may be a rational target for anti-angiogenic therapy of HCC.

275 is for individualized treatment decisions in anti-angiogenic therapy of neovascular AMD and perhaps o

276 inhibition provides a novel opportunity for anti-angiogenic therapy to complement VEGF or VEGFR2 blo

277 d leaky tumour vasculature might also enable anti-angiogenic therapy to increase the efficacy of radi

278 their involvement in adaptive resistance to anti-angiogenic therapy via enhanced metastasis.

279 ed, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the

280 t transport in the external tissue (e.g., by anti-angiogenic therapy) increased tumor fragmentation m

281 atified by germline BRCA status and previous anti-angiogenic therapy, to receive olaparib capsules 40

282 refractoriness found in cancers resistant to anti-angiogenic therapy.

283 ory strategies could improve the efficacy of anti-angiogenic therapy.

284 ogression and could be potential targets for anti-angiogenic therapy.

285 nts that mediate refractoriness of tumors to anti-angiogenic therapy.

286 rently being explored in clinical trials for anti-angiogenic therapy.

287 larization correlated with downregulation of anti-angiogenic thrombospondin-1 (Tsp1) and related prot

288 At least half of patients fail to respond to anti-angiogenic treatment and the response duration is v

289 Anti-angiogenic treatment is generally well tolerated bu

290 ct of oral anti-cancer drug delivery through anti-angiogenic treatment strategies.

291 or growth kinetics influence the response to anti-angiogenic treatment targeting VEGF.

292 c intervention that could complement current anti-angiogenic treatment.

293 accurately predicts the tumor's response to anti-angiogenic treatment.

294 favorable balance in pro-angiogenic BDNF and anti-angiogenic TSP-1/CD36.

295 SP1 with either full-length TSP1 or 3TSR, an anti-angiogenic TSP1 fragment, suppresses heightened vas

296 palliative effect for VEGF/VEGFR1-targeting anti-angiogenic tumor therapies.

297 ostic estimates and inverse correlation with anti-angiogenic tyrosine-kinase inhibition in comparison

298 rs 1, 2, and 3 and PDGF receptors like other anti-angiogenic tyrosine-kinase inhibitors approved for

299 trations of angiogenic (VEGF-A, Ang1, Ang2), anti-angiogenic (VEGF-A165b ) and lymphangiogenic (VEGF-

300 eported to generate angiogenic (VEGFxxx) and anti-angiogenic (VEGFxxxb) isoforms.